MYCOF

Mydecine Innovations Group Inc.

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

VANCOUVER, British Columbia, Dec. 18, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by... Read More...

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

VANCOUVER, British Columbia, Oct. 31, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is... Read More...

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

London, UK --News Direct-- Mydecine Innovations Group Inc Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector.Bartch explains that Mydecine focuses on developing "second generation" drugs de... Read More...

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

VANCOUVER, British Columbia, Oct. 10, 2023 -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD... Read More...

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

VANCOUVER, British Columbia, Oct. 05, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to ... Read More...

Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

DENVER, Dec. 12, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated Septemb... Read More...

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

DENVER, Aug. 19, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has... Read More...

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

DENVER, Aug. 15, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months ended June 30, 2022. Financial Results for the Six Months Ended June 30, 2022 Net Los... Read More...

Mydecine To Attend March Investor Conferences

DENVER, March 03, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the company will be attending three conferences for investors in March – the 34th Annual Roth Conf... Read More...

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

VANCOUVER, British Columbia, Jan. 07, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the company has engaged JBN Partners, LLC (“JBN”) to in... Read More...

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

DENVER, Dec. 09, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered into an agreement with an investor to complete a non-brokered priv... Read More...

Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update

--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety of Indications -- DENVER, Nov. 16, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a ... Read More...

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

DENVER, Nov. 03, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of a technology patent that allows for the creation of formulations th... Read More...

Mydecine to Participate in Wonderland: Miami on November 8-9, 2021

DENVER, Oct. 29, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the treatment of mental health disorders and addiction, today announced that it will participate in Microdose’s Wonderland: Miami to be held at the Adrienne Arsht... Read More...

Mydecine Completes Spin-Out of U.S. Cannabis Assets

DENVER, Oct. 01, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has completed its previously announced spin-out transaction (the “Transaction”) of ALT House Cannabis Inc. (“Sp... Read More...

Mydecine to Participate in Upcoming Conferences in September 2021

DENVER, Sept. 02, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in three upcoming conferences: H... Read More...

Mydecine to Participate in Upcoming Investor Events in August 2021

DENVER, July 28, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will pa... Read More...

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

DENVER, July 21, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent fo... Read More...

Mydecine Innovations Group Announces Launch of Mindleap Version 2.0

The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and ac... Read More...

Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th

DENVER, June 23, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will pa... Read More...

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...

Mydecine Innovations Group Shares Intellectual Property Update

Company files seven provisional patent applications with United States Patent and Trademark OfficeDENVER, Jan. 07, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natur... Read More...

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

DENVER, Jan. 05, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

DENVER, Dec. 21, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has engaged ethica CRO ("ethica CRO"), a full-servic... Read More...

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybinDENVER, Dec. 08, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company com... Read More...

Mydecine Innovations Group to Restate Financial Statements

VANCOUVER, British Columbia, Nov. 24, 2020 -- Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month periods ended March 31, 2020 and June 30, 2020, any corresponding management’s discussion a... Read More...

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 19, 2020 -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the ... Read More...

Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

VANCOUVER, British Columbia, Oct. 07, 2020 -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of mat... Read More...

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

Picture 1Figure 1Figure 1DENVER, Sept. 30, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:... Read More...

Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42c4893d-6232-4d13-9d58-b3098cc222bbDENVER, Sept. 24, 2020 --  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform wil... Read More...

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

DENVER, Sept. 15, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value.Topics that the special committee will discuss include, but limited to, a potential spin out of certain company ... Read More...

Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

DENVER, Sept. 03, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine", “MIG”) is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for an additional 120 days.Under the ter... Read More...